ClinicalTrials.gg
CompletedNCT02075515Updated May 14, 2021Results posted

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

A Phase 3 interventional study of Herpes Zoster vaccine (GSK 1437173A) in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 8 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
651
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.

Enrollment
16th of 37
651 · median 450
Started
2014
with 3 others
Phase 3
25 of 44
none open now
Registered
25th of 44
by date

Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 16th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 in phase 3, and was the 25th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Herpes Zoster by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.

03

Conditions studied

  • Herpes Zoster
  • Herpes Zoster Vaccine

Browse trials for

Keywords

  • Safety
  • Zoster
  • Immunogenicity
  • Adults
  • Consistency
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination.
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of \< 20 mg/day is allowed. Inhaled, topical and intra-articular are allowed.
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine (E.g. inactivated and subunit vaccines) within 8 days prior to or within 14 days after either dose of study vaccine.
  • Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous vaccination against HZ or varicella.
  • Planned administration during the study of an HZ or varicella vaccine other than the study vaccine.
  • History of HZ.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Acute disease and/or fever at the time of enrollment.

    • Fever is defined as temperature ≥ 37.5°C (99.5°F) on oral, axillary or tympanic route, or ≥ 38.0°C (100.4°F) on rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating females.
  • Females planning to become pregnant or planning to discontinue precautions (if of ) before Month 4.
  • Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
651 participants (actual)

Study arms

  • Experimental
    HZ/su Lot A

    Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.

    Biological: Herpes Zoster vaccine (GSK 1437173A)

  • Experimental
    HZ/su Lot B

    Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.

    Biological: Herpes Zoster vaccine (GSK 1437173A)

  • Experimental
    HZ/su Lot C

    Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.

    Biological: Herpes Zoster vaccine (GSK 1437173A)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value

    Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was ≥ 97 milli international units per milliliter (mIU/mL).

    Time frame: At Month 3

Secondary outcomes

  1. Anti-gE Humoral Immunogenicity

    Anti-gE antibody concentrations, were determined by ELISA, expressed as Geometric Mean Concentrations (GMCs), in milli international units per milliliter (mIU/mL).

    Time frame: At Month 0 and Month 3

  2. Number of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA

    Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: At Month 3

  3. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activities.

    Time frame: Within 7 days (Days 0-6) after each vaccine dose and across doses

  4. Number of Days With Any Solicited Local Symptoms

    The number of days with any local symptoms reported during the solicited post-vaccination period.

    Time frame: During the 7 days (Days 0-6) after each vaccine dose

  5. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature= temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within 7 days (Days 0-6) after each vaccine dose and across doses

  6. Number of Days With Any Solicited General Symptoms

    The number of days with any general symptoms reported during the solicited post-vaccination period.

    Time frame: During the 7 days (Days 0-6) after each vaccine dose

  7. Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

    Time frame: From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 until study end (Month 14)

  8. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During 30 days (Days 0-29) after each vaccination

  9. Number of Subjects With Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 to study end (Month 14)

07

Results

Posted May 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Started218217216
Completed214212208
Not completed458
Withdrew: Serious adverse event111
Withdrew: Non-serious adverse event010
Withdrew: Withdrawal by subject201
Withdrew: Lost to follow-up136

Outcome measures

PrimaryNumber of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value

Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was ≥ 97 milli international units per milliliter (mIU/mL).

Time frame:
At Month 3
Reported as:
Number · Subjects
Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value210210202
Statistical analysis
  • GSK1437173A Lot A Group vs GSK1437173A Lot B Group · ANCOVA · Adjusted gmc ratio: 0.97 · 95% CI 0.86 to 1.09
  • GSK1437173A Lot A Group vs GSK1437173A Lot C Group · ANCOVA · Adjustd gmc ratio: 0.96 · 95% CI 0.85 to 1.08
  • GSK1437173A Lot B Group vs GSK1437173A Lot C Group · ANCOVA · Adjusted gmc ratio: 0.99 · 95% CI 0.88 to 1.10
SecondaryAnti-gE Humoral Immunogenicity

Anti-gE antibody concentrations, were determined by ELISA, expressed as Geometric Mean Concentrations (GMCs), in milli international units per milliliter (mIU/mL).

Time frame:
At Month 0 and Month 3
Reported as:
Geometric mean · mIU/mL
Anti-gE Humoral Immunogenicity
mIU/mLGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Anti-gE, Month 01378.4 (1180.0 to 1610.0)1166.5 (1005.5 to 1353.4)1381.2 (1190.9 to 1601.9)
Anti-gE, Month 359556.1 (54587.6 to 64976.7)60733.8 (55995.2 to 65873.3)62058.3 (57422.3 to 67068.7)
SecondaryNumber of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA

Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
At Month 3
Reported as:
Number · Subjects
Number of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Number of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA201205197
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activities.

Time frame:
Within 7 days (Days 0-6) after each vaccine dose and across doses
Reported as:
Number · Subjects
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Any Pain, Dose 1160179166
Grade 3 Pain, Dose 1467
Any Redness, Dose 1294841
Grade 3 Redness, Dose 1111
Any Swelling, Dose 1243326
Grade 3 Swelling, Dose 1001
Any Pain, Dose 2155152155
Grade 3 Pain, Dose 218137
Any Redness, Dose 2384743
Grade 3 Redness, Dose 2322
Any Swelling, Dose 2222825
Grade 3 Swelling, Dose 2311
Any Pain, Across Doses188196185
Grade 3 Pain, Across Doses221613
Any Redness, Across Doses526862
Grade 3 Redness, Across Doses433
Any Swelling, Across Doses384439
Grade 3 Swelling, Across Doses312
SecondaryNumber of Days With Any Solicited Local Symptoms

The number of days with any local symptoms reported during the solicited post-vaccination period.

Time frame:
During the 7 days (Days 0-6) after each vaccine dose
Reported as:
Median · Days
Number of Days With Any Solicited Local Symptoms
DaysGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Pain post-Dose 12.0 (2.0 to 3.5)3.0 (2.0 to 3.0)3.0 (2.0 to 4.0)
Pain post-Dose 22.0 (2.0 to 4.0)2.0 (2.0 to 3.0)2.0 (2.0 to 3.0)
Redness post-Dose 12.0 (2.0 to 3.0)3.0 (1.5 to 3.0)2.0 (2.0 to 4.0)
Redness post-Dose 23.0 (2.0 to 4.0)3.0 (2.0 to 3.0)3.0 (2.0 to 3.0)
Swelling post-Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 3.0)3.0 (2.0 to 4.0)
Swelling post-Dose 23.0 (2.0 to 4.0)3.0 (2.0 to 4.0)3.0 (2.0 to 3.0)
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature= temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within 7 days (Days 0-6) after each vaccine dose and across doses
Reported as:
Number · Subjects
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Any Fatigue, Dose 1666864
Grade 3 Fatigue, Dose 1544
Related Fatigue, Dose 1626358
Any Gastrointestinal, Dose 1232226
Grade 3 Gastrointestinal, Dose 1104
Related Gastrointestinal, Dose 1192023
Any Headache, Dose 1636849
Grade 3 Headache, Dose 1544
Related Headache, Dose 1596343
Any Myalgia, Dose 1858976
Grade 3 Myalgia, Dose 1434
Related Myalgia, Dose 1717862
Any Shivering, Dose 1312122
Grade 3 Shivering, Dose 1140
Related Shivering, Dose 1301921
Any Temperature, Dose 1282322
Grade 3 Temperature, Dose 1000
Related Temperature, Dose 1242119
Any Fatigue, Dose 2918582
Grade 3 Fatigue, Dose 21476
Related Fatigue, Dose 2898076
Any Gastrointestinal, Dose 2333429
Grade 3 Gastrointestinal, Dose 2225
Related Gastrointestinal, Dose 2292928
Any Headache, Dose 2748066
Grade 3 Headache, Dose 29115
Related Headache, Dose 2697663
Any Myalgia, Dose 2999183
Grade 3 Myalgia, Dose 220117
Related Myalgia, Dose 2858176
Any Shivering, Dose 2676044
Grade 3 Shivering, Dose 21157
Related Shivering, Dose 2665943
Any Temperature, Dose 2433425
Grade 3 Temperature, Dose 2201
Related Temperature, Dose 2403325
Any Fatigue, Across Doses114109107
Grade 3 Fatigue, Across Doses181110
Related Fatigue, Across Doses111102103
Any Gastrointestinal, Across Doses464550
Grade3 Gastrointestinal,Across Doses329
Any Headache, Across Doses10110889
Grade 3 Headache, Across Doses13139
Related Headache, Across Doses9510182
Any Myalgia, Across Doses128119113
Grade 3 Myalgia, Across Doses241210
Related Myalgia, Across Doses112107102
Any Shivering, Across Doses806760
Grade 3 Shivering, Across Doses1277
Related Shivering, Across Doses796558
Any Temperature, Across Doses594943
Grade 3 Temperature, Across Doses201
Related Temperature, Across Doses534641
Related Gastrointestinal, Across Doses413946
SecondaryNumber of Days With Any Solicited General Symptoms

The number of days with any general symptoms reported during the solicited post-vaccination period.

Time frame:
During the 7 days (Days 0-6) after each vaccine dose
Reported as:
Median · Days
Number of Days With Any Solicited General Symptoms
DaysGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Fatigue post-Dose 12.0 (1.0 to 2.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Fatigue post-Dose 22.0 (1.0 to 2.0)2.0 (1.0 to 3.0)1.5 (1.0 to 2.0)
Gastrointestinal symptoms post-Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Gastrointestinal symptoms post-Dose 21.0 (1.0 to 2.0)1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Headache post-Dose 11.0 (1.0 to 2.0)1.5 (1.0 to 2.0)2.0 (1.0 to 3.0)
Headache post-Dose 21.0 (1.0 to 2.0)1.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
Myalgia post-Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Myalgia post-Dose 22.0 (1.0 to 3.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Shivering post-Dose 11.0 (1.0 to 2.0)2.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Shivering post-Dose 21.0 (1.0 to 2.0)1.0 (1.0 to 1.5)1.0 (1.0 to 2.0)
Temperature post-Dose 11.0 (1.0 to 1.0)1.0 (1.0 to 2.0)1.0 (1.0 to 1.0)
Temperature post-Dose 21.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 2.0)
SecondaryNumber of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

Time frame:
From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 until study end (Month 14)
Reported as:
Number · Subjects
Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
pIMDs from Month 0 to Month 3301
pIMDs from Month 4 to Month 14202
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During 30 days (Days 0-29) after each vaccination
Reported as:
Number · Subjects
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Any AE(s)726976
Grade 3 AE(s)13159
Related AE(s)232227
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 to study end (Month 14)
Reported as:
Number · Subjects
Number of Subjects With Any Serious Adverse Events (SAEs)
SubjectsGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
SAEs from Month 0 to Month 3574
SAEs from Month 4 to Month 1410816

Adverse events

Collected over Solicited local and general symptoms: within 7 days (Days 0-6) after each vaccination; Unsolicited AEs: during 30 days (Days 0-29) after each vaccination; SAEs: from first vaccination up to study end (Month 0-Month 14).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Lot A Group—13/218 (6%)202/218 (92.7%)
GSK1437173A Lot B Group—14/217 (6.5%)201/217 (92.6%)
GSK1437173A Lot C Group—20/216 (9.3%)198/216 (91.7%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
Cardiac failure congestiveCardiac disorders2/2180/2172/216
SepsisInfections and infestations0/2182/2171/216
Back painMusculoskeletal and connective tissue disorders0/2182/2170/216
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2182/2170/216
CholelithiasisHepatobiliary disorders2/2181/2170/216
LeukocytosisBlood and lymphatic system disorders0/2180/2171/216
Acute myocardial infarctionCardiac disorders1/2180/2171/216
Myocardial infarctionCardiac disorders0/2180/2171/216
Sinus node dysfunctionCardiac disorders0/2180/2171/216
Supraventricular tachycardiaCardiac disorders0/2180/2171/216
Most frequent other events
Most frequent other events
EventGSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C Group
PainGeneral disorders188/218196/217185/216
MyalgiaMusculoskeletal and connective tissue disorders128/218119/217113/216
FatigueGeneral disorders114/218109/217107/216
HeadacheNervous system disorders101/218108/21789/216
ChillsGeneral disorders80/21867/21761/216
ErythemaSkin and subcutaneous tissue disorders55/21870/21762/216
PyrexiaGeneral disorders60/21850/21743/216
Gastrointestinal disorderGastrointestinal disorders46/21845/21750/216
SwellingGeneral disorders38/21844/21740/216
Upper respiratory tract infectionInfections and infestations7/2187/21711/216

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C GroupTotal
Mean64.8 ± 8.864.3 ± 9.464.4 ± 8.864.5 ± 8.99
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A Lot A GroupGSK1437173A Lot B GroupGSK1437173A Lot C GroupTotal
Female116130114360
Male10287102291
08

Study locations

8 sites
  • GSK Investigational Site
    Mesa, Arizona 85213, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Milford, Massachusetts 01757, United States
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Wilrijk, 2610, Belgium
  • GSK Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 0G1, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
09

References and documents

Publications

  • Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine. 2017 Dec 4;35(48 Pt B):6700-6706. doi: 10.1016/j.vaccine.2017.10.017. Epub 2017 Oct 24. PubMed 29079101 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Apr 2015, 8 months.

Results were first posted in May 2017, 2 years after primary completion. A results delay was requested in Nov 2015.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 8 months is below that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2014
First posted
Mar 3, 2014
StartActual
Aug 13, 2014
Primary completionActual
Apr 29, 2015
CompletionActual
Apr 25, 2016
Results delay requested
Nov 12, 2015
Results first posted
May 24, 2017
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02075515
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Aug 13, 2014
Primary completion
Apr 29, 2015
Completion
Apr 25, 2016
Results posted
May 24, 2017
Last update
May 14, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Herpes Zoster Vaccine

Start the discussion